blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP4236931

EP4236931 - COMPOSITIONS COMPRISING TETRAHYDROCANNABINOL FOR TREATING ACUTE RESPIRATORY FAILURE AND/OR ACUTE RESPIRATORY DISTRESS SYNDROME [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  15.08.2025
Database last updated on 21.03.2026
FormerThe patent has been granted
Status updated on  06.09.2024
FormerGrant of patent is intended
Status updated on  25.04.2024
FormerExamination is in progress
Status updated on  20.10.2023
FormerRequest for examination was made
Status updated on  04.08.2023
FormerThe international publication has been made
Status updated on  07.05.2022
Formerunknown
Status updated on  03.12.2021
Most recent event   Tooltip13.03.2026Lapse of the patent in a contracting state
New state(s): HU		published on 15.04.2026 [2026/16]
Applicant(s)For all designated states
Nagy, Aurangzeb Nafees
3012 S. Durango Dr.
Las Vegas, Nevada 89117 / US
[2023/36]
Inventor(s)01 / see applicant
...
 [2023/36]
Representative(s)Wildhack & Jellinek Patentanwälte GmbH
Landstraßer Hauptstraße 50
1030 Wien / AT
[N/P]
Former [2024/41]Wildhack & Jellinek Patentanwälte
Patentanwälte OG
Landstraßer Hauptstraße 50
1030 Wien / AT
Former [2023/36]Wildhack & Jellinek
Patentanwälte OG
Landstraßer Hauptstraße 50
1030 Wien / AT
Application number, filing date21811683.829.10.2021
[2023/36]
WO2021US57433
Priority number, dateUS202063107201P29.10.2020         Original published format: US 202063107201 P
US202063107873P30.10.2020         Original published format: US 202063107873 P
US202063128755P21.12.2020         Original published format: US 202063128755 P
US202163134919P07.01.2021         Original published format: US 202163134919 P
US202163235659P20.08.2021         Original published format: US 202163235659 P
US202163252912P06.10.2021         Original published format: US 202163252912 P
[2023/36]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2022094330
Date:05.05.2022
Language:EN
[2022/18]
Type: A2 Application without search report 
No.:EP4236931
Date:06.09.2023
Language:EN
The application published by WIPO in one of the EPO official languages on 05.05.2022 takes the place of the publication of the European patent application.
[2023/36]
Type: B1 Patent specification 
No.:EP4236931
Date:09.10.2024
Language:EN
[2024/41]
Search report(s)International search report - published on:EP21.07.2022
ClassificationIPC:A61K31/15, A61K31/198, A61K31/352, A61K31/4045, A61K38/21, A61P11/00
[2023/36]
CPC:
A61K31/352 (EP,IL); A61K31/658 (KR,US); A61K31/15 (EP,IL,KR);
A61K31/198 (EP,IL,KR); A61K31/4045 (EP,IL); A61K38/21 (KR);
A61K38/212 (EP,IL); A61K38/215 (EP,IL); A61K38/217 (EP,IL);
A61P11/00 (EP,IL,KR); A61P29/00 (KR); A61K2300/00 (IL,KR) (-)
C-Set:
A61K31/15, A61K2300/00 (EP);
A61K31/198, A61K2300/00 (EP);
A61K31/352, A61K2300/00 (EP);
A61K31/4045, A61K2300/00 (EP);
A61K38/212, A61K2300/00 (EP);
A61K38/215, A61K2300/00 (EP);
A61K38/217, A61K2300/00 (EP)
(-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2023/36]  
Extension statesBANot yet paid
MENot yet paid
Validation statesKHNot yet paid
MANot yet paid
MDNot yet paid
TNNot yet paid
TitleGerman:ZUSAMMENSETZUNGEN ENTHALTEND TETRAHYDROCANNABINOL ZUR BEHANDLUNG VON AKUTER ATEMINSUFFIZIENZ UND/ODER AKUTEM ATEMNOTSYNDROM[2024/20]
English:COMPOSITIONS COMPRISING TETRAHYDROCANNABINOL FOR TREATING ACUTE RESPIRATORY FAILURE AND/OR ACUTE RESPIRATORY DISTRESS SYNDROME[2023/36]
French:COMPOSITIONS COMPRENANT DU TETRAHYDROCANNABINOL DESTINÉES AU TRAITEMENT D'INSUFFISANCE RESPIRATOIRE AIGUË ET/OU DU SYNDROME DE DÉTRESSE RESPIRATOIRE AIGUË[2024/20]
Former [2023/36]ZUSAMMENSETZUNGEN MIT TETRAHYDROCANNABINOL ZUR BEHANDLUNG VON AKUTER ATEMINSUFFIZIENZ UND/ODER AKUTEM ATEMNOTSYNDROM
Former [2023/36]COMPOSITIONS ET MÉTHODES DE TRAITEMENT D'INSUFFISANCE RESPIRATOIRE AIGUË ET/OU DE SYNDROME DE DÉTRESSE RESPIRATOIRE AIGUË À L'AIDE DE TÉTRAHYDROCANNABINOL ET COMPOSITIONS LE COMPRENANT
Entry into regional phase26.05.2023National basic fee paid 
26.05.2023Designation fee(s) paid 
26.05.2023Examination fee paid 
Examination procedure26.05.2023Amendment by applicant (claims and/or description)
26.05.2023Examination requested  [2023/36]
26.05.2023Date on which the examining division has become responsible
20.10.2023Despatch of a communication from the examining division (Time limit: M04)
19.02.2024Reply to a communication from the examining division
26.04.2024Communication of intention to grant the patent
26.08.2024Fee for grant paid
26.08.2024Fee for publishing/printing paid
26.08.2024Receipt of the translation of the claim(s)
Opposition(s)10.07.2025No opposition filed within time limit [2025/38]
Fees paidRenewal fee
10.10.2023Renewal fee patent year 03
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU29.10.2021
CZ09.10.2024
ES09.10.2024
HR09.10.2024
MC09.10.2024
PL09.10.2024
SK09.10.2024
SM09.10.2024
IE29.10.2024
CH31.10.2024
NO09.01.2025
RS09.01.2025
GR10.01.2025
IS09.02.2025
[2026/16]
Former [2025/48]CZ09.10.2024
ES09.10.2024
HR09.10.2024
MC09.10.2024
PL09.10.2024
SK09.10.2024
SM09.10.2024
IE29.10.2024
CH31.10.2024
NO09.01.2025
RS09.01.2025
GR10.01.2025
IS09.02.2025
Former [2025/36]CZ09.10.2024
ES09.10.2024
HR09.10.2024
MC09.10.2024
PL09.10.2024
SK09.10.2024
SM09.10.2024
CH31.10.2024
NO09.01.2025
RS09.01.2025
GR10.01.2025
IS09.02.2025
Former [2025/35]ES09.10.2024
HR09.10.2024
MC09.10.2024
PL09.10.2024
SM09.10.2024
CH31.10.2024
NO09.01.2025
RS09.01.2025
GR10.01.2025
IS09.02.2025
Former [2025/33]ES09.10.2024
HR09.10.2024
MC09.10.2024
PL09.10.2024
SM09.10.2024
NO09.01.2025
RS09.01.2025
GR10.01.2025
IS09.02.2025
Former [2025/32]ES09.10.2024
HR09.10.2024
PL09.10.2024
SM09.10.2024
NO09.01.2025
RS09.01.2025
GR10.01.2025
IS09.02.2025
Former [2025/23]ES09.10.2024
HR09.10.2024
PL09.10.2024
NO09.01.2025
RS09.01.2025
GR10.01.2025
IS09.02.2025
Cited inInternational search[XPI] WO2021191888  (I P ISRAEL PATENTS LTD et al.)
 [XPI] WO2021209998  (MOLAD AMI et al.)
 [E] WO2021231810  (UNIV RES INST INC AUGUSTA et al.)
 [E] WO2021224924  (EPM IP INC et al.)
 [XYI] WO2020188551  (BOL PHARMA LTD et al.)
 [XAYI]   MOHAMMED AMIRA ET AL: "[Delta]9-Tetrahydrocannabinol Prevents Mortality from Acute Respiratory Distress Syndrome through the Induction of Apoptosis in Immune Cells, Leading to Cytokine Storm Suppression", INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, vol. 21, no. 17, 1 January 2020 (2020-01-01), pages 6244, XP055896316, Retrieved from the Internet DOI: 10.3390/ijms21176244

DOI:   http://dx.doi.org/10.3390/ijms21176244
 [Y]   RAMLALL VIJENDRA ET AL: "Melatonin is significantly associated with survival of intubated COVID-19 patients", MEDRXIV, 18 October 2020 (2020-10-18), pages 1 - 37, XP055896548, Retrieved from the Internet [retrieved on 20220301], DOI: 10.1101/2020.10.15.20213546

DOI:   http://dx.doi.org/10.1101/2020.10.15.20213546
 [AD]   TANAKA TOSHIO ET AL: "Immunotherapeutic implications of IL-6 blockade for cytokine storm", IMMUNOTHERAPY, FUTURE MEDICINE, LONDON, vol. 8, no. 8, 1 July 2016 (2016-07-01), pages 959 - 970, XP008184780, ISSN: 1750-7448, [retrieved on 20160706], DOI: 10.2217/IMT-2016-0020

DOI:   http://dx.doi.org/10.2217/imt-2016-0020
 [XPAI]   NAGARKATTI PRAKASH ET AL: "Use of Cannabinoids to Treat Acute Respiratory Distress Syndrome and Cytokine Storm Associated with Coronavirus Disease-2019", FRONTIERS IN PHARMACOLOGY, vol. 11, 6 November 2020 (2020-11-06), XP055896198, DOI: 10.3389/fphar.2020.589438

DOI:   http://dx.doi.org/10.3389/fphar.2020.589438
 [XP]   RAJ VINIT ET AL: "Assessment of antiviral potencies of cannabinoids against SARS-CoV-2 using computational and in vitro approaches", INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, ELSEVIER BV, NL, vol. 168, 5 December 2020 (2020-12-05), pages 474 - 485, XP086448442, ISSN: 0141-8130, [retrieved on 20201205], DOI: 10.1016/J.IJBIOMAC.2020.12.020

DOI:   http://dx.doi.org/10.1016/j.ijbiomac.2020.12.020
 [Y]   ZHOU QIONG ET AL: "Interferon-alpha2b Treatment for COVID-19", FRONTIERS IN IMMUNOLOGY, vol. 11, 15 May 2020 (2020-05-15), Lausanne, CH, XP055849492, ISSN: 1664-3224, DOI: 10.3389/fimmu.2020.01061

DOI:   http://dx.doi.org/10.3389/fimmu.2020.01061
 [Y]   RANGEL-MNDEZ JORGE-AARN; ROSA-ESTER MOO-PUC: "N-acetylcysteine as a potential treatment for COVID-19", FUTURE MICROBIOLOGY, vol. 15, no. 11, 1 July 2020 (2020-07-01), GB, pages 959 - 962, XP055759564, ISSN: 1746-0913, DOI: 10.2217/fmb-2020-0074

DOI:   http://dx.doi.org/10.2217/fmb-2020-0074
 [A]   HOERTEL NICOLAS ET AL: "SSRIs and SNRIs and Risk of Death or Intubation in COVID-19: Results from an Observational Study", MEDRXIV, 14 July 2020 (2020-07-14), pages 1 - 37, XP055926695, Retrieved from the Internet [retrieved on 20220531], DOI: 10.1101/2020.07.09.20143339

DOI:   http://dx.doi.org/10.1101/2020.07.09.20143339
 [A]   CLINICALTRIALS.GOV: "A Double-blind, Placebo-controlled Clinical Trial of Fluvoxamine for Symptomatic Individuals With COVID-19 Infection", 13 April 2020 (2020-04-13), pages 1 - 8, XP055928475, Retrieved from the Internet [retrieved on 20220607]
Examination  CLINICALTRIALS.GOV: "NCT04342663 A Double-blind, Placebo-controlled Clinical Trial of Fluvoxamine for Symptomatic Individuals With COVID-19 Infection | Results Posted", 9 July 2021 (2021-07-09), pages 1 - 15, XP093092044, Retrieved from the Internet [retrieved on 20231016] [P]
by applicantUS200162631072
 US197362631078
 US195562631287
 US201962631349
 US195962632356
 US201262632529
   S. M. BERGE ET AL.: "Pharmaceutical Salts", J. PHARM. SCI., vol. 66, 1977, pages 1 - 19, XP002675560, DOI: 10.1002/jps.2600660104

DOI:   http://dx.doi.org/10.1002/jps.2600660104
   "Remington's Pharmaceutical Sciences", 1980, MACK PUBLISHING, pages: 1530 - 1533
   "The United States Pharmacopeia: The National Formulary", 1999
   WHO CORONAVIRUS DISEASE (COVID-19) DASHBOARD, 20 December 2020 (2020-12-20), Retrieved from the Internet
   "Parasher A. COVID-19: Current understanding of its pathophysiology, clinical presentation and treatment", POSTGRAD MED J., 25 September 2020 (2020-09-25)
   WINDSOR, M., HERE'S A PLAYBOOK FOR STOPPING DEADLY CYTOKINE STORM SYNDROME - THE REPORTER, 2019
   COOMES EAHAGHBAYAN H: "Interleukin-6 in Covid-19: A systematic review and meta-analysis", REV MED VIROL., vol. 30, no. 6, November 2020 (2020-11-01), pages 1 - 9
   TANAKA TNARAZAKI MKISHIMOTO T.: "Immunotherapeutic implications of IL-6 blockade for cytokine storm", IMMUNOTHERAPY, vol. 8, no. 8, July 2016 (2016-07-01), pages 959 - 70, XP008184780, DOI: 10.2217/imt-2016-0020

DOI:   http://dx.doi.org/10.2217/imt-2016-0020
   GUARALDI GMESCHIARI MCOZZI-LEPRI AMILIC JTONELLI RMENOZZI MFRANCESCHINI ECUOMO GORLANDO GBORGHI V: "Tocilizumab in patients with severe COVID-19: a retrospective cohort study", LANCET RHEUMATOL., vol. 2, no. 8, August 2020 (2020-08-01), pages e474 - e484, XP055803327, DOI: https://doi.org/10.1016/S2665-9913(20)30173-9

DOI:   http://dx.doi.org/https://doi.org/10.1016/S2665-9913(20)30173-9
   SHEPPARD MLASKOU FSTAPLETON PPHADAVI SDASGUPTA B: "Tocilizumab (Actemra", HUM VACCIN IMMUNOTHER., vol. 13, no. 9, 2 September 2017 (2017-09-02), pages 1972 - 1988
   VINK HDULING BR: "Capillary endothelial surface layer selectively reduces plasma solute distribution volume", AM J PHYSIOL HEART CIRC PHYSIOL., vol. 278, no. 1, January 2000 (2000-01-01), pages H285 - 9
   ONO SEGAWA GKABASHIMA K: "Regulation of blood vascular permeability in the skin", INFLAMM REGEN., vol. 37, 2017, pages 11
   BIOLOGICSCORP, FAB ANTIBODY FRAGMENT PRODUCTION - FAB/FAB' EXPRESSION - BIOLOGICSCORP, 20 December 2020 (2020-12-20)
   SUNG JYHONG JHKANG HSCHOI ILIM SDLEE JKSEOK JHLEE JHHUR GM: "Methotrexate suppresses the interleukin-6 induced generation of reactive oxygen species in the synoviocytes of rheumatoid arthritis", IMMUNOPHARMACOLOGY, vol. 47, no. 1, April 2000 (2000-04-01), pages 35 - 44
   REGGIO PH: "Endocannabinoid binding to the cannabinoid receptors: what is known and what remains unknown", CURR MED CHEM., vol. 17, no. 14, 2010, pages 1468 - 1486
   MARINOL, FDA PRESCRIBING INFORMATION, SIDE EFFECTS AND USES, 1 March 2020 (2020-03-01), Retrieved from the Internet
   ATWOOD BKSTRAIKER AMACKIE K.: "CB : therapeutic target-in-waiting", PROG NEUROPSYCHOPHARMACOL BIOL PSYCHIATRY, vol. 38, no. 1, 2012, pages 16 - 20
   NAGARKATTI PPANDEY RRIEDER SAHEGDE VLNAGARKATTI M: "Cannabinoids as novel anti-inflammatory drugs", FUTURE MED CHEM., vol. 1, no. 7, 2009, pages 1333 - 1349, XP055533169, DOI: 10.4155/fmc.09.93

DOI:   http://dx.doi.org/10.4155/fmc.09.93
   KLEIN TWNEWTON CWIDEN RFRIEDMAN H: "Delta 9-tetrahydrocannabinol injection induces cytokine-mediated mortality of mice infected with Legionella pneumophila", J PHARMACOL EXP THER., vol. 267, no. 2, November 1993 (1993-11-01), pages 635 - 40
   MOHAMMED AALGHETAA HSULTAN MSINGH NPNAGARKATTI PNAGARKATTI M: "Administration of A9-Tetrahydrocannabinol (THC) Post-Staphylococcal Enterotoxin B Exposure Protects Mice from Acute Respiratory Distress Syndrome and Toxicity", FRONT PHARMACOL. 2020, vol. 11, 16 June 2020 (2020-06-16), pages 893
   AW DSILVA ABPALMER DB: "Immunosenescence: emerging challenges for an ageing population", IMMUNOLOGY, vol. 120, no. 4, 2007, pages 435 - 446
   GOLD JEBAUMGARTL WHOKYAY RALICHT WEFIDEL PL JRNOVERR MCTILLEY LPHURLEY DJRADA BASHFORD JW: "Analysis of Measles-Mumps-Rubella (MMR) Titers of Recovered COVID-19 Patients", MBIO, vol. 11, no. 6, 20 November 2020 (2020-11-20), pages e02628 - 20
   PRADHAN AOLSSON PE: "Sex differences in severity and mortality from COVID-19: are males more vulnerable?", BIOL SEX DIFFER, vol. 11, no. 1, 18 September 2020 (2020-09-18), pages 53
   LI LKRAJEWSKI SREED JCCHOI YS: "The apoptosis and proliferation of SAC-activated B cells by IL-10 are associated with changes in Bcl-2, Bcl-xL, and Mcl-1 expression", CELL IMMUNOL., vol. 178, no. 1, 25 May 1997 (1997-05-25), pages 33 - 41, XP029582251, DOI: 10.1006/cimm.1997.1129

DOI:   http://dx.doi.org/10.1006/cimm.1997.1129
   JOFFRE JYEH CCWONG ETHETE MXU FZLATANOVA ILLOYD EKOBZIK LLEGRAND MHELLMAN J: "Activation of CB1R Promotes Lipopolysaccharide-Induced IL-10 Secretion by Monocytic Myeloid-Derived Suppressive Cells and Reduces Acute Inflammation and Organ Injury", J IMMUNOL., vol. 204, no. 12, 15 June 2020 (2020-06-15), pages 3339 - 3350
   BASU AMANNING WGMULLAHY J: "Comparing alternative models: log versus Cox proportional hazard?", HEALTH ECON, vol. 13, 2004, pages 749 - 65
   NAGARKATTI ET AL., USE OF CANNABINOIDS TO TREAT ACUTE RESPIRATORY DISTRESS SYNDROME AND CYTOKINE STORM ASSOCIATED WITH CORONAVIRUS DISEASE, 6 November 2019 (2019-11-06), pages 2020
   RAO ET AL., TETRAHYDROCANNABINOL ATTENUATES STAPHYLOCOCCAL ENTEROTOXIN B-INDUCED INFLAMMATORY LUNG INJURY AND PREVENTS MORTALITY IN MICE BY MODULATION OF MIR-17-92 CLUSTER AND INDUCTION OF T-REGULATORY CELLS, 10 February 2015 (2015-02-10), Retrieved from the Internet
   MOHAMMED ET AL., ADMINISTRATION OF A9-TETRAHYDROCANNABINOL (THC) POST-STAPHYLOCOCCAL ENTEROTOXIN B EXPOSURE PROTECTS MICE FROM ACUTE RESPIRATORY DISTRESS SYNDROME AND TOXICITY, 16 June 2020 (2020-06-16), Retrieved from the Internet
   MOHAMMED ET AL., PROTECTIVE EFFECTS OF A9-TETRAHYDROCANNABINOL AGAINST ENTEROTOXIN-INDUCED ACUTE RESPIRATORY DISTRESS SYNDROME IS MEDIATED BY MODULATION OF MICROBIOTA, 4 August 2020 (2020-08-04), Retrieved from the Internet
   MOHAMMED ET AL., 9-TETRAHYDROCANNABINOL PREVENTS MORTALITY FROM ACUTE RESPIRATORY DISTRESS SYNDROME THROUGH THE INDUCTION OF APOPTOSIS IN IMMUNE CELLS, LEADING TO CYTOKINE STORM SUPPRESSION, 28 August 2020 (2020-08-28), Retrieved from the Internet
   BASU SRAY ADITTEL BN: "Cannabinoid receptor 2 is critical for the homing and retention of marginal zone B lineage cells and for efficient T-independent immune responses", JOURNAL OF IMMUNOLOGY, vol. 187, no. 11, December 2011 (2011-12-01), pages 5720 - 32
   HARVEY BPGEE RJHABERMAN AMSCHLOMCHIK MJMAMULA MJ: "Antigen presentation and transfer between B cells and macrophages", EUR J IMMUNOL., vol. 37, no. 7, July 2007 (2007-07-01), pages 1739 - 51, XP071224389, DOI: 10.1002/eji.200636452

DOI:   http://dx.doi.org/10.1002/eji.200636452
   DEN HAANJOKE M.MKRAAL. GEORG: "Innate Immune Functions of Macrophage Subpopulations in the Spleen", JOURNAL OF INNATE IMMUNITY, vol. 4, no. 5-6, 2012, pages 437 - 445
   BLAESS MKAISER LSOMMERFELD OCSUK RDEIGNER HP: "Drugs, Metabolites, and Lung Accumulating Small Lysosomotropic Molecules: Multiple Targeting Impedes SARS-CoV-2 Infection and Progress to COVID-19", INT J MOL SCI., vol. 22, no. 4, 11 February 2021 (2021-02-11), pages 1797
   ROSEN DASEKI SMFERNANDES-CASTENEDA ABEITER RMECCLES JDWOODFOLK JAGAULTIER A: "Modulation of the Sigma-1 Receptor-IRE1 Pathway Is Beneficial in Preclinical Models of Inflammation and Sepsis", SCI. TRANSL. MED., vol. 11, 2019, pages eaau5266, XP055663201, DOI: 10.1126/scitranslmed.aau5266

DOI:   http://dx.doi.org/10.1126/scitranslmed.aau5266
   VELA, JOSE MIGUEL: "Repurposing Sigma-I Receptor Ligands for COVID-19 Therapy?", FRONT PHARMACOL, vol. 11, 2020, pages 582310
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.